Table 1.
Rates of reported PV DNA findings in skin samples from cats using PCR
| Study | Primer set | BISC | Viral plaques | SCC | ISCC | OSCC | Other lesions | Normal skin |
|---|---|---|---|---|---|---|---|---|
| Kidney, 2001 [44] | NO1/NO2 | 0/50 (0 %) | ||||||
| E5+/E5− | 0/50 (0 %) | |||||||
| IFNR-2/IDNT-2 | 0/50 (0 %) | |||||||
| Antonsson, 2002 [41] | FAP59/FAP64 | 0/5 (0 %) | ||||||
| Nespeca, 2006 [10] | PapF/PapR | 1/21 (5 %) | 0/22 (0 %) | 0/11 (0 %) | ||||
| CP4/CP5/PPF1 | 5/21 (24 %) | 4/22 (18 %) | 0/11 (0 %) | |||||
| Munday, 2007 [15] | FAP59/FAP64 | 11/18 (61 %) | 0/15 (0 %) | 0/3 (0 %) | ||||
| IFNR-2/IDNT-2 | 9/11 (82 %) | 0/15 (0 %) | 0/3 (0 %) | |||||
| 5/18 (28 %) | ||||||||
| Munday, 2008 [18] | a | 20/20 (100 %) | 17/20 (85 %) | 3/17 (18 %) | ||||
| Munday, 2008 [33] | FAP59/FAP64 | 2/2 (100 %) | ||||||
| MY09/MY11 | 2/2 (100 %) | |||||||
| JMPF/JMPR | 2/2 (100 %) | |||||||
| Lange, 2009 [11] | A16/A37 | 3/3 (100 %) | ||||||
| Munday, 2009 [31] | FAP59/FAP64 | 1/20 (5 %) | 0/20 (0 %) | |||||
| IFNR-2/IDNT-2 | 0/20 (0 %) | 0/20 (0 %) | ||||||
| MY09/MY11 | 0/20 (0 %) | 0/20 (0 %) | ||||||
| Munday, 2009 [21] | FAP59/FAP64 | 1/1 (100 %) | ||||||
| JMPF/JMPR | 1/1 (100 %) | |||||||
| Anis, 2010 [4] | b | 3/3 (100 %) | 5/5 (100 %) | 1/1 (100 %) | 1/1 (100 %) | |||
| 3/3 (100 %) | 4/5 (80 %) | |||||||
| Munday, 2009 [24] | MY09/MY11 | 0/44 (0 %) | ||||||
| JMPF/JMPR | 34/88 (39 %) c | |||||||
| Munday, 2010 [19] | MY09/MY11 | 4/14 (29 %) | 0/14 (0 %) | |||||
| FAP59/FAP64 | 4/14 (29 %) | 0/14 (0 %) | ||||||
| JMPF/JMPR | 14/14 (100 %) | 1/14 (7 %) | ||||||
| Munday, 2010 [45] | MY09/MY11 | 4/7 (57 %) | 0/120 (0 %) | |||||
| jmpSA-F/jmpSA-R | 6/7 (86 %) | 0/120 (0 %) | ||||||
| Munday, 2011 [22] | MY09/MY11 | 7/70 (10 %) | ||||||
| JMPF/JMPR | 33/70 (48 %) | |||||||
| Munday, 2011 [23] | a | 14/14 (100 %) | 8/8 (100 %) | 12/18 (67 %) | 1/14 (7 %) | |||
| Munday, 2011 [46] | FAP59/FAP64 | 0/30 (0 %) | ||||||
| MY09/MY11 | 0/30 (0 %) | |||||||
| O’Neill, 2011 [5] | d | 7/22 (32 %) | 11/74 (15 %) | 2/12 (17 %) | ||||
| 4/22 (18 %) | 4/74 (5 %) | |||||||
| Schwittick, 2011 [47] | a | 1/1 (100 %) | ||||||
| Munday, 2013 [12] | FAP59/FAP64 | 0/1 (0 %) | ||||||
| JMPF/JMPR | 0/1 (0 %) | |||||||
| MY09/MY11 | 1/1 (100 %) | |||||||
| JMY2F/JMY2R | 1/1 (100 %) | |||||||
| Dunowska, 2014 [13] | FAP59/FAP64 | 0/1 (0 %) | ||||||
| MY09/MY11 | 1/1 (100 %) | |||||||
| Unnamed set | 1/1 (100 %) | |||||||
| Thomson, 2015 [25] | E7SF/E7SR | 11/11 (100 %) 20/22 (91 %) |
FdPV2 DNA detection are written in italic
BISC Bowenoid in situ carcinoma, SCC squamous cell carcinoma, ISCC infiltrative squamous cell carcinoma (when defined in study), other lesions = actinic keratosis, allergic dermatitis, apocrine gland cyst, apocrine gland cystadenoma, dermatophytosis, dysplasia, eosinophilic granuloma, eosinophilic plaques, feline leprosy, fibrosarcoma, glossitis, granulomatous dermatitis, hyperplastic tonsil, hypersensitivity dermatitis, mast cell tumour, melanoma, periodontal disease, plasmacytic stomatitis, sarcoids, trichoblastoma, ulcerative gingivitis
anested PCR with FAP59/FAP64 and JMPF/JMPR
bHPV1, HPV2, HPV4, HPV7, HPV8, HPV10, HPV15
cequals 23/44 cats (52 %)
dFAP59/FAP64 and nested PCR with CP65/CP70 and CP66/CP69